Latham & Watkins advised Erasca on the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca’s License Agreement With Novartis
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
Cytokinetics’ $540 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its...
Pfizer’s $25 Million Equity Investment in Zentalis Pharmaceuticals
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...
UCB’s Acquisition of Zogenix
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
Galderma’s Acquisition of Alastin Skincare
Ropes & Gray advised Galderma on the deal, while Latham & Watkins advised ALASTIN. Galderma, one of the world’s largest independent dermatology companies, executed its acquisition...
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...